DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data

Artificial Intelligence in Medicine

Volumn 63, Issue 1, 2015, Pages 41-49

  Martínez, Víctor ^a   Navarro, Carmen ^a   Cano, Carlos ^a   Fajardo, Waldo ^a   Blanco, Armando ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Data integration; Disease networks; Drug repositioning; Flow propagation; Network based prioritization

Indexed keywords

COMPLEX NETWORKS; HETEROGENEOUS NETWORKS; TESTING;

BIOLOGICAL INFORMATION; CROSS-VALIDATION TESTS; DRUG REPOSITIONING; HETEROGENEOUS DATA; HETEROGENEOUS DATA INTEGRATIONS; NETWORK PRIORITIZATION; PRIORITIZATION; SIMULTANEOUS INTEGRATION;

DATA INTEGRATION;

CISPLATIN; DONEPEZIL; GABAPENTIN; METHOTREXATE; RISPERIDONE;

ARTICLE; COMPUTER NETWORK; COMPUTER PROGRAM; DATA ANALYSIS; DRUG INFORMATION; DRUG REPOSITIONING; DRUG SCREENING; PRIORITY JOURNAL; VALIDATION PROCESS; AREA UNDER THE CURVE; BIOLOGY; COMPUTER SIMULATION; DATA MINING; FACTUAL DATABASE; HUMAN; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; SYSTEM ANALYSIS; THEORETICAL MODEL; VALIDATION STUDY;

AREA UNDER CURVE; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DATA MINING; DATABASES, FACTUAL; DRUG REPOSITIONING; HUMANS; MODELS, THEORETICAL; REPRODUCIBILITY OF RESULTS; ROC CURVE; SYSTEMS INTEGRATION;

EID: 84924014923     PISSN: 09333657     EISSN: 18732860     Source Type: Journal    
DOI: 10.1016/j.artmed.2014.11.003     Document Type: Article

References (61)

1. Dudley J., Deshpande T., Butte A. Exploiting drug-disease relationships for computational drug repositioning. Brief Bioinform 2011, 12(4):303-311.
2. Ashburn T., Thor K. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004, 3(8):673-683.
3. Sardana D., Zhu C., Zhang M., Gudivada R.C., Yang L., Jegga A.G. Drug repositioning for orphan diseases. Brief Bioinform 2011, 12(4):346-356.
4. Graul A.I., Sorbera L., Pina P., Tell M., Cruces E., Rosa E., et al. The year's new drugs & biologics-2009. Drug News Perspect 2010, 23(1):7-36.
5. Persidis A. The benefits of drug repositioning. Drug Discov 2011, 12:9-12.
6. Mucke H.A. Drug repositioning: extracting added value from prior r&d investments, Technical report 2010, Cambridge Healthtech Institute.
7. Cheng F., Liu C., Jiang J., Lu W., Li W., Liu G., et al. Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol 2012, 8(5):e1002503.
8. Iorio F., Bosotti R., Scacheri E., Belcastro V., Mithbaokar P., Ferriero R., et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci 2010, 107(33):14621-14626.
9. Hu G., Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS ONE 2009, 4(8):e6536.
10. Emig D., Ivliev A., Pustovalova O., Lancashire L., Bureeva S., Nikolsky Y., et al. Drug target prediction and repositioning using an integrated network-based approach. PLoS ONE 2013, 8(4):e60618.
11. Iorio F., Rittman T., Ge H., Menden M., Saez-Rodriguez J. Transcriptional data: a new gateway to drug repositioning?. Drug Discov Today 2013, 18(7):350-357.
12. Lamb J., Crawford E., Peck D., Modell J., Blat I., Wrobel M., et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Sci Signal 2006, 313(5795):1929-1935.
13. Ma D.-L., Chan D.S.-H., Leung C.-H. Drug repositioning by structure-based virtual screening. Chem Soc Rev 2013, 42(5):2130-2141.
14. Medina-Franco J.L., Giulianotti M.A., Welmaker G.S., Houghten R.A. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today 2013, 18(9):495-501.
15. Reddy A.S., Zhang S. Polypharmacology: drug discovery for the future. Exp Rev Clin Pharmacol 2013, 6(1):41-47.
16. Achenbach J., Tiikkainen P., Franke L., Proschak E. Computational tools for polypharmacology and repurposing. Future Med Chem 2011, 3(8):961-968.
17. Xie L., Xie L., Kinnings S.L., Bourne P.E. Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 2012, 52:361-379.
18. von Eichborn J., Murgueitio M., Dunkel M., Koerner S., Bourne P., Preissner R. Promiscuous: a database for network-based drug-repositioning. Nucleic Acids Res 2011, 39(Suppl. 1):D1060-D1066.
19. Yang L., Agarwal P. Systematic drug repositioning based on clinical side-effects. PLoS ONE 2011, 6(12):e28025.
20. Gottlieb A., Stein G., Ruppin E., Sharan R. Predict: a method for inferring novel drug indications with application to personalized medicine. Mol Syst Biol 2011, 7(1):496.
21. Chiang A., Butte A. Systematic evaluation of drug-disease relationships to identify leads for novel drug uses. Int J Clin Pharmacol Ther 2009, 86(5):507-510.
22. Aravind L. Guilt by association: contextual information in genome analysis. Genome Res 2000, 10(8):1074-1077.
23. Quackenbush J. Microarraysguilt by association. Science 2003, 302(5643):240-241.
24. Walker M.G., Volkmuth W., Klingler T.M. Pharmaceutical target discovery using guilt-by-association: schizophrenia and Parkinsons disease genes. Proc Int Conf Intell Syst Mol Biol 1999, 282-286.
25. Swinney D., Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011, 10(7):507-519.
26. Hasan S., Bonde B.K., Buchan N.S., Hall M.D. Network analysis has diverse roles in drug discovery. Drug Discov Today 2012, 17(15):869-874.
27. Mathur S., Dinakarpandian D. Drug repositioning using disease associated biological processes and network analysis of drug targets. AMIA annual symposium proceedings, vol. 2011 2011, 305.
28. Chen X., Liu M.-X., Yan G.-Y. Drug-target interaction prediction by random walk on the heterogeneous network. Mol BioSyst 2012, 8(7):1970-1978.
29. Diaz-Beltran L., Cano C., Wall D.P., Esteban F.J. Systems biology as a comparative approach to understand complex gene expression in neurological diseases. Behav Sci 2013, 3(2):253-272.
30. Martí nez V., Cano C., Blanco A. Prophnet: a generic prioritization method through propagation of information. BMC Bioinform 2014, 15(Suppl. 1):S5.
31. Vanunu O., Sharan R. A propagation based algorithm for inferring gene-disease associations. Proceedings of German conference on bioinformatics 2008, 52-54.
32. Navlakha S., Kingsford C. The power of protein interaction networks for associating genes with diseases. Bioinformatics 2010, 26(8):1057-1063.
33. Knox C., Law V., Jewison T., Liu P., Ly S., Frolkis A., et al. Drugbank 3.0: a comprehensive resource for omics research on drugs. Nucleic Acids Res 2011, 39(Suppl. 1):D1035-D1041.
34. Lin D. An information-theoretic definition of similarity. Proceedings of the 15th international conference on machine learning 1998, 296-304.
35. Schriml L.M., Arze C., Nadendla S., Chang Y.-W.W., Mazaitis M., Felix V., et al. Disease ontology: a backbone for disease semantic integration. Nucleic Acids Res 2012, 40(D1):D940-D946.
36. Chatr-aryamontri A., Breitkreutz B.-J., Heinicke S., Boucher L., Winter A., Stark C., et al. The biogrid interaction database: 2013 update. Nucleic Acids Res 2013, 41(D1):D816-D823.
37. Peng K., Xu W., Zheng J., Huang K., Wang H., Tong J., et al. The disease and gene annotations (dga): an annotation resource for human disease. Nucleic Acids Res 2013, 41(D1):D553-D560.
38. Beck J., Shultz E. The use of relative operating characteristic (roc) curves in test performance evaluation. Arch Pathol Lab Med 1986, 110(1):13-20.
39. Zweig M.H., Campbell G. Receiver-operating characteristic (roc) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39(4):561-577.
40. Krantz A. Diversification of the drug discovery process. Nat Biotechnol 1998, 16(13):1294.
41. Feagan B.G., Rochon J., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., et al. Methotrexate for the treatment of crohn's disease. N Engl J Med 1995, 332(5):292-297.
42. Fonseca V.A., Handelsman Y., Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence Diabetes. Obes Metab 2010, 12(5):384-392.
43. Pollack M.H., Matthews J., Scott E.L. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998, 155(7):992-993.
44. Silver D.P., Richardson A.L., Eklund A.C., Wang Z.C., Szallasi Z., Li Q., et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol 2010, 28(7):1145-1153.
45. Aarsland D., Laake K., Larsen J., Janvin C. Donepezil for cognitive impairment in parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002, 72(6):708-712.
46. Jacobsen F.M., et al. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995, 56(9):423.
47. Van Bever H., Stevens W. Nedocromil sodium cream in the treatment of atopic dermatitis. Eur J Pediatr 1989, 149(1):74.
48. Williams H. Multi-centre clinical trial of nedocromil sodium in reversible obstructive airways disease in adults: a general practitioner collaborative study. Curr Med Res Opin 1989, 11(7):417-426.
49. Mabry R.L. Topical pharmacotherapy for allergic rhinitis: nedocromil. Am J Otolaryngol 1993, 14(6):379-381.
50. Chesnut C. Tiludronate: development as an osteoporosis therapy. Bone 1995, 17(5):S517-S519.
51. McClung M., Tou C., Goldstein N., Picot C. Tiludronate therapy for paget's disease of bone. Bone 1995, 17(5):S493-S496.
52. Moreau M., Rialland P., Pelletier J.-P., Martel-Pelletier J., Lajeunesse D., Boileau C., et al. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther 2011, 13(3):R98.
53. Dumon J., Magritte A., Body J.-J. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 1991, 15(3):257-266.
54. Heufelder A., Wenzel B., Bahn R. Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in graves' retroocular fibroblasts. J Clin Endocrinol Metab 1992, 74(4):737-742.
55. Mandel S.J., Brent G.A., Larsen P.R. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993, 119(6):492-502.
56. Erfurth E.M.T., Ericsson U.-B.C., Egervall K., Lethagen S.R. Effect of acute desmopressin and of long-term thyroxine replacement on haemostasis in hypothyroidism. Clin Endocrinol 1995, 42(4):373-378.
57. Skowsky W.R., Kikuchi T.A. The role of vasopressin in the impaired water excretion of myxedema. Am J Med 1978, 64(4):613-621.
58. Mei H., Xia T., Feng G., Zhu J., Lin S.M., Qiu Y. Opportunities in systems biology to discover mechanisms and repurpose drugs for cns diseases. Drug Discov Today 2012, 17(21):1208-1216.
59. Davis A.P., Murphy C.G., Johnson R., Lay J.M., Lennon-Hopkins K., Saraceni-Richards C., et al. The comparative toxicogenomics database: update 2013. Nucleic Acids Res. 2012, 41:D1104-D1114.
60. Grubbs F.E. Procedures for detecting outlying observations in samples. Technometrics 1969, 11(1):1-21.
61. Tanimoto T.T. IBM internal report 1957, 1957.